We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.
|Published (Last):||22 April 2008|
|PDF File Size:||12.42 Mb|
|ePub File Size:||20.8 Mb|
|Price:||Free* [*Free Regsitration Required]|
Dhooge14 M. Randomization must be performed eiramos 35 days from date of definitive surgery. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Kuehne26 C. New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability.
Main objectives To examine in a randomized trial, whether the addition of ifosfamide and etoposide IE to post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a poor histological response to 10 weeks of pre-operative chemotherapy.
It is permissible to administer up to two additional MTX courses and have the patient remain eligible for randomization.
Response classification was dichotomised: There were limits to the accessibility of the trial for osteosarcoma patients. However, the agents chosen highlight the paucity of new or investigational products appropriate to include in phase III trials.
P therapeutic intensification in non-metastatic osteosarcoma: Randomisation was offered to eligible registered patients with reported histological response. Abstract Background Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.
Page Not Found
Lau27 G. Greater patient involvement at the design stage may help in the future. The feasibility of delivering intensive chemotherapy for a rare cancer in multiple centres within a Good Clinical Practice framework is amply demonstrated here.
J Natl Cancer Inst. No matching affiliation detected. Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. Standard descriptive statistics are used. The international studygroup recommands until further notice to treat all patients with the standardarm MAP. There was some variability in proportion randomised between groups: Bielack2 N.
We describe the study, its population and the initial treatment of registered patients. Kager25 T. Three deaths were treatment-related two from infective complications and one from toxic epidermal necrolysis secondary to methotrexate and three occurred after surgery.
Teot38 M. In other areas, the study has highlighted where improvement is needed. Gorlick19 G. With patients with resectable osteosarcoma randomised, it doubled the size of the previous largest RCT in this population and accrual was completed in around 6 years.
Page Not Found | MRC Clinical Trials Unit at UCL
However, it is also clear that the treatment burden of MAP is exceptionally high, reflected in levels of grade 3—4 haematological and non-haematological toxicity. Support Center Support Center. G D Letson H.
The treatment-related death rate of 0. Pathology at diagnostic biopsy and surgery. This article has been cited by other articles in PMC. Treatment will be allocated using permuted blocks, stratified by group, site of primary tumor and presence of metastases.